{"id":"NCT00477672","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","officialTitle":"A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2009-06","completion":"2009-07","firstPosted":"2007-05-24","resultsPosted":"2014-03-26","lastUpdate":"2017-05-17"},"enrollment":298,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease Psychosis"],"interventions":[{"type":"DRUG","name":"Pimavanserin tartrate (ACP-103)","otherNames":[]},{"type":"DRUG","name":"Pimavanserin tartrate (ACP-103)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"1","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.","primaryOutcome":{"measure":"Antipsychotic Efficacy","timeFrame":"Each study visit (i.e. Days 1, 8, 15, 29 and 42)","effectByArm":[{"arm":"Placebo","deltaMin":-5.9,"sd":7.9},{"arm":"Pimavanserin 10 mg","deltaMin":-5.8,"sd":9.77},{"arm":"Pimavanserin 40 mg","deltaMin":-6.7,"sd":7.87}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":78,"countries":["United States","Bulgaria","France","India","Russia","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":98},"commonTop":["Fall","Dizziness","Nausea","Orthostatic hypotension","Headache"]}}